Pharmacokinetics and Pharmacodynamics of GS‐9350: A Novel Pharmacokinetic Enhancer Without Anti‐HIV Activity

@article{Mathias2010PharmacokineticsAP,
  title={Pharmacokinetics and Pharmacodynamics of GS‐9350: A Novel Pharmacokinetic Enhancer Without Anti‐HIV Activity},
  author={Anita A Mathias and Polina German and Bernard P. Murray and L. Wei and A. Jain and Steve West and DR Warren and James Hui and Brian P. Kearney},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2010},
  volume={87}
}
GS‐9350 is a new chemical entity under development as a potent, mechanism‐based inhibitor of human cytochrome P450 3A (CYP3A) isoforms. Its intended use is to increase the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. Unlike ritonavir, which is in current clinical use for this purpose, GS‐9350 is devoid of anti‐HIV activity. The pharmacokinetics of GS‐9350 and its efficacy in increasing systemic exposure of the probe CYP3A substrate midazolam were examined in… 
Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug–drug interaction potential of CYP3A4 substrates
TLDR
Simulations of the hepatic and gut CYP3A4 abundance after multiple oral dosing of ritonavir indicated that a 3‐day treatment with ritonvir 100 mg twice daily is sufficient to reach maximal CYP 3A4 inhibition and subsequent systemic exposure increase of a CYP2A4 substrate, resulting in the reliable estimation of fm,CYP3A 4.
Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
TLDR
The PBPK results suggest there is a potential for DDI between dasabuvir and clopidogrel, but the magnitude is not expected to be clinically relevant.
Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.
TLDR
A review summarizes the findings on the relative contribution of the heme-ligating moiety, side chains and the terminal group of ritonavir-like molecules to the ligand binding process, and highlights strategies for a structure-guided design of CYP3A4 inactivators.
Evidence‐based choice of ritonavir as index CYP3A inhibitor in drug‐drug interaction studies
  • D. Greenblatt
  • Biology, Medicine
    Journal of clinical pharmacology
  • 2016
TLDR
A review of the available published evidence clearly indicates that ritonavir is the best choice as an alternative index inhibitor for CYP3A inhibitors.
The Drug–Drug Interaction Profile of Presatovir
TLDR
Data support coadministration of presatovir with inhibitors of P‐gp, BCRP, OATP1B1/1B3, or CYP3A, but not with moderate or strong CYP 3A4 inducers.
Pharmacokinetic Enhancers in HIV Therapeutics
TLDR
Current knowledge of ritonavir and cobicistat, two pharmacokinetic enhancers or boosting agents used in HIV therapy, are summarized and clinically relevant drug regimens and ongoing trials are discussed.
A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
TLDR
The current model, which incorporates formulation characteristics and mechanistic disposition parameters, can be used to assess the DDI potential of CYP3A4/5 and CYP2D6 substrates administered with a twice-daily dose of 100 mg of ritonavir for 14 days.
In vitro inhibition of human UGT isoforms by ritonavir and cobicistat
TLDR
Ritonavir and cobicistat are unlikely to produce clinically important drug interactions involving drugs metabolized to glucuronide conjugates by UGT1A1,1A3, 1A6, 1B9, 2B4 and 2B7.
Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK‐guided drug development approach
TLDR
Saturation of gut and liver metabolism by CYP3A4, and saturation of hepatic uptake by OATP1B1/3, seem to account for the observed nonlinear PK of simeprevir.
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.
TLDR
Findings signify a dominant role for CYP3A-mediated metabolism in the elimination of ibrutinib, and suggest a role for pharmacological inhibitors of this pathway to intentionally modulate the plasma levels and improve the therapeutic use of this clinically important agent.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure
TLDR
A critical understanding is provided of ritonavir's dose–response relationship for inhibition of CYP3A activity in humans to boost the effects of protease inhibitors at doses of 100–400 mg per day.
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
TLDR
The large increase in the plasma concentrations of other protease inhibitors when coadministered with ritonavir forms the basis of rational dual protease inhibitor regimens, providing patients with 2 potent drugs at significantly reduced doses and less frequent dosage intervals.
Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P‐glycoprotein in HIV‐infected Patients
TLDR
CYP3A, CYP2D6, and P‐glycoprotein are profoundly inhibited in patients receiving ritonavir boosted lopinavir, and the covariates investigated are not useful for a priori dose selection.
Drug-Metabolizing Enzyme Inhibition by Ketoconazole Does Not Reduce Interindividual Variability of CYP3A Activity as Measured by Oral Midazolam
TLDR
Use of a CYP3A inhibitor to standardize dosing of CYp3A substrates may not be feasible in clinical practice because of the low level of well characterized impact of ketoconazole on interindividual variability.
Rapid Clinical Induction of Hepatic Cytochrome P4502B6 Activity by Ritonavir
TLDR
The results show that ritonavir induces human CYP2B6 activity, which may have significant implications for drug interactions and clarify previously unexplained interactions.
Up‐regulation of P‐glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line
TLDR
Investigation of transport and inductive properties on efflux drug transporters of two PIs, atazanavir and ritonavir, at the blood–brain barrier by using a human brain microvessel endothelial cell line, hCMEC/D3 found cellular accumulation of these PIs appears to be primarily limited by P‐gp efflux activity.
Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers
TLDR
LPV/r therapy results in modest induction of CYP1A2 and CYP2C9 and potent induction of cytochrome P450 activity and increasing doses of concomitant medications metabolized by these enzymes may be necessary.
Induction Effects of Ritonavir: Implications for Drug Interactions
TLDR
It is important for clinicians to be aware of drugs potentially impacted by ritonavir therapy to identify and manage these interactions and to distinguish the relative effects of additional medications unless well-designed, 3-way studies are conducted.
Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia
TLDR
The virtual inhibitory quotient, which incorporates both baseline viral resistance and the level of drug exposure in plasma, was superior to either baseline resistance or drug exposure alone in predicting the virologic response.
Lopinavir/ritonavir Reduces Bupropion Plasma Concentrations in Healthy Subjects
TLDR
LPV/r exposure is unaffected by a single dose of bupropion, and a probable mechanism for this interaction is the concurrent induction of cytochrome P450 2B6 and UDP‐glucuronosyltransferase enzymes.
...
1
2
3
4
...